April 17, 2021


Advances in world technology

MediWound Offers Progress Update on Its EscharEx Clinical Growth Plan

Period 2 Adaptive Layout Examine Sample Dimensions Diminished to 120 Patients

Interim Evaluation Predicted in Mid-2021 and Completion of Enrollment by 12 months-Close 2021

Protocol Submitted to Fda for Pharmacology Medical Review with Details Anticipated in Second Fifty percent 2021

YAVNE, Israel, Jan. 11, 2021 (World NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a completely built-in biopharmaceutical firm bringing revolutionary therapies to deal with unmet needs in serious burn off and wound administration, nowadays offered an update on its EscharEx® medical growth method.

Thanks to COVID-19 linked enrollment delays and potentially foreseeable future pandemic linked implications on the perform of its clinical research, the company is accelerating its EscharEx section 2 adaptive structure examine, for the treatment method of venous leg ulcers (VLUs), by altering its enrollment concentrate on to 120 patients, down from the 174 at first planned. The sample dimension adjustment is supported by the assessment of the favourable results generated in a recent in-vivo research, comparing EscharEx to a commercially enzymatic debriding agent, and the debridement efficacy success demonstrated in a former section 2 medical research with first technology EscharEx. The company carries on to actively recruit sufferers and reiterates its expectation for an interim assessment in mid-2021. As a consequence of the adjustment, analyze duration is predicted to shorten and the corporation anticipates finishing affected individual enrollment by year-finish 2021.

MediWound not too long ago submitted a protocol to the Food and drug administration for a pharmacology examine and is getting ready to initiate this research in the to start with 50 percent of 2021. The study is an open label, one arm analyze assessing the pharmacological effects of EscharEx in up to 15 clients with VLUs or diabetic foot ulcers (DFUs), which includes the consequences on biofilm stress and wound irritation, as properly as the impact of EscharEx on wound therapeutic development. The company anticipates reporting facts from this review in the second 50 percent of 2021.

“We are incredibly pleased with the progress we have manufactured in our EscharEx growth software in 2020, even with the problems posed by the COVID-19 pandemic,” mentioned Sharon Malka, Main Executive Officer of MediWound. “Chronic wounds existing a major unmet health-related want for lots of individuals, and we feel that EscharEx can have a significant influence on chronic wound management, providing considerable positive aspects for people, healthcare pros and payers. We welcome 2021 with good anticipation and glimpse forward to the pharmacology review knowledge as properly as the interim assessment and completion of patient enrollment in our phase 2 adaptive structure analyze.”

About EscharEx
EscharEx is a topical biological drug applicant for the debridement of chronic and other difficult-to-mend wounds. In two stage 2 trials, EscharEx has demonstrated safety and efficacy in the debridement of several long-term and other tricky-to-recover wounds, inside a few everyday apps. EscharEx active compound (API) is a focus of proteolytic enzymes enriched in bromelain. The system of action of EscharEx is mediated by the proteolytic enzymes that cleaves and gets rid of the necrotic tissue and prepare the wound mattress for healing. EscharEx is an investigational products, now less than a U.S. phase 2 adaptive layout review.

About MediWound Ltd.
MediWound is a thoroughly integrated biopharmaceutical business concentrated on developing, producing and commercializing novel therapeutics based on its patented proteolytic enzyme technological innovation to handle unmet requires in the fields of serious burns, persistent and other hard-to-recover wounds. MediWound’s very first impressive biopharmaceutical product, NexoBrid®, non-surgically and speedily eliminates burn up eschar with no harming viable tissue. The products has gained advertising and marketing authorization from the European Medicines Agency as effectively as the Israeli, Argentinian, South Korean, Russian and Peruvian Ministries of Health for eschar removal (debridement) in older people with deep partial-thickness and/or whole-thickness thermal burns. On June 29, 2020, a biological license application (BLA) was submitted to the U.S. Fda and was assigned a Prescription Drug Consumer Price Act (PDUFA) target date of June 29, 2021. MediWound’s next impressive product, EscharEx is a topical organic drug prospect for the debridement of long-term and other really hard-to-recover wounds employing the very same proteolytic enzyme know-how as NexoBrid. In two Period 2 research, EscharEx has shown basic safety and efficacy in the debridement of various persistent and other difficult-to-recover wounds, in just a couple everyday apps. For more data, please stop by www.mediwound.com.

Cautionary Note Regarding Forward-Wanting Statements

MediWound caution you that all statements other than statements of historical reality bundled in this press launch that address pursuits, gatherings, or developments that we anticipate, consider or foresee will or might arise in the long run are ahead-hunting statements. Despite the fact that we consider that we have a affordable basis for the ahead-on the lookout statements contained herein, they are primarily based on latest expectations about potential functions impacting us and are matter to hazards, assumptions, uncertainties and variables, all of which are difficult to predict and quite a few of which are over and above our manage. Actual effects could vary materially from these expressed or implied by the ahead-on the lookout statements in this push launch. These statements are usually, but are not usually, made through the use of terms or phrases these as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and very similar text or phrases, or potential or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.

Specially, this push launch includes ahead-looking statements about the predicted development, development, aims, expectations, and commercial potential of NexoBrid and EscharEx. Among the the components that may result in results to be materially unique from people mentioned herein are the inherent uncertainties affiliated with the timing and carry out of clinical trials and products growth things to do the timing or likelihood of regulatory approvals the capacity to properly produce and commercialize NexoBrid, which include its industrial progress opportunity and the sector desire for the merchandise aggressive developments regardless of whether Fda will provide internet marketing approval for NexoBrid in the United States the capability to successfully develop and commercialize EscharEx, the structure of the Section 2 analyze, the timing of the interim evaluation and the completion of enrollment, the time of commencing the pharmacological analyze and the success , the impression of applicable laws and restrictions and the uncertainties associated with the scope, scale and duration of the affect of the COVID-19 pandemic. For illustration, we are unable to predict how the pandemic will affect the general health care infrastructure, such as the potential to recruit patients, the skill to carry out the reports in health-related websites and the pace with which governmental agencies, such as the Fda, will assessment and approve regulatory submissions. Supplemental federal government-imposed quarantines and prerequisites to “shelter at home” or other incremental mitigation initiatives also may well influence our ability to resource provides for our functions or our capability or capacity to manufacture, market and support the use of NexoBrid and EscharEx in the long term.

These and other significant factors are reviewed in increased element in MediWound’s yearly report on Sort 20-F for the year ended December 31, 2019, submitted with the Securities and Exchange Commission (“SEC”) on February 25, 2020, Quarterly Stories on Sort 6-K and other filings with the SEC from time-to-time. These forward-hunting statements replicate MediWound’s recent views as of the date hereof and MediWound undertakes, and especially disclaims, any obligation to update any of these forward-on the lookout statements to mirror a improve in their respective sights or situations or circumstances that come about soon after the date of this launch apart from as expected by regulation.